HempFusion Wellness completes its CBD pilot trial related to chronic inflammation

HempFusion Wellness Inc (TSE:CBD.U) (OTCQX:CBDHF) (FRA:8OO) said it has completed a pilot study, in collaboration with Kansas-based Inflammatory Markers Laboratory (IML), which assessed the effect of the HempFusion formulation CBD Capsules as it relates to a combination of anti-inflammatories in lowering the results of the chronic inflammation test. 

HempFusion said results of the pilot study have shown potential promise in the area of inflammatory markers and the possible effects on exaggerated inflammation. 

“We are committed to furthering research in the area of hemp-derived CBD and this pilot trial and soon to be published white paper reinforces our continued focus on the safe and effective use of hemp-derived CBD products,” HempFusion Wellness CEO Jason Mitchell said in a statement. 

READ: HempFusion utilizing the power of whole-food hemp nutrition 

IML Director Gordon Ens also commented, stating: “Our laboratory has demonstrated the effectiveness of numerous products in reducing thromboxane production. I was pleased to see a CBD product show such a significant reduction of thromboxane in this pilot trial.”

HempFusion also said it has released a white paper, which is expected to be published shortly, titled Oral Formulation May Modulate Thromboxane Production, illustrating the potential of tracking and elucidating biomarkers sensitive to inflammation, in addition to how novel compounds and formulas modulate the expression of these markers. The paper is co-authored by Ens and University of Alabama Professor George Fritsma.

HempFusion noted that it is dedicated to research related to toxicology safety, which is evident through its involvement and co-sponsoring of the ValidCare Human Observational Safety Study, which it believes is the largest CBD toxicology study of its kind ever completed to date.

The company added that it continues to focus on research & development, pilot studies, and clinical trials, to advance the science of CBD.

HempFusion distributes its family of brands, including HempFusion, Probulin Probiotics, Biome Research, and HF Labs, to around 4,000 retail locations across all 50 states of the US and select international locations.

In addition, HempFusion’s wholly-owned subsidiary Probulin Probiotics is one of the fastest-growing probiotics companies in the US, according to data technology company SPINS. The subsidiary offers the unique MAKtrek 3-D system that ensures more probiotics arrive alive.

Contact Sean at [email protected]

Story by ProactiveInvestors